DiagnaMed Enhances CERVAI Brain Health Platform Commercialization Efforts In Canada
FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.
DiagnaMed Holdings (CSE: DMED) continues to progress with the commercialization of its CERVAI Brain Health AI Platform. The platform has recently been accepted into the Hamilton Ecosystem to Accelerate and Leverage Trials of Health Innovation, which is also known as the HEALTHI program.
The HEALTHI program has been designed to assist in developing relationships with clinicians and hospital facilities ahead of conducting clinical trials or commercialization efforts in Canada. Developed in partnership with the National Research Council of Canada, the program connects two research hospitals, Hamilton Health Sciences and The Research Institute at St. joe’s Hamilton, with businesses that are entering the commercialization stage.
“We are pleased to be accepted into the HEALTHI program to accelerate our commercialization initiatives of CERVAI™, a novel brain health AI platform, and validate its potential in improving overall brain health. As part of our commercialization plans, we continue leveraging expertise from Canada’s respected life sciences ecosystem to improve CERVAI™’s positioning and global expansion goals,” commented DiagnaMed CEO Fabio Chianelli.
Acceptance into the HEALTHI program is expected to accelerate clinical research as well as commercialization efforts of the CERVAI platform in Canada.
READ: DiagnaMed Begins Test Launch of CERVAI
CERVAI has been developed to assess risk levels for the development of Alzheimer’s and other neurological issues through the use of a series of tests. These tests produce three results, referred to as a Resilience Index, a Vulnerability Index, and a Number-Symbol Coding Task. When brought together, these results assist in assessing a patients risk for developing neurological issues by providing a snapshot of brain health.
A test pilot program is underway across Canada and the US, which is available at 25 clinics currently.
DiagnaMed Holdings last traded at $0.05 on the CSE.
FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of DiagnaMed Holdings. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
